Oral Dosage Form New Animal Drugs; Lufenuron Tablets

FederalRegulations

Ask Donna

How this section applies to your facts.

Federal Register › Vol. 60 › 60 FR 362

This text was captured on Sep 30, 2026. It is a snapshot, not a live feed, so check the official code before relying on it.

Text

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 520

Oral Dosage Form New Animal Drugs; Lufenuron Tablets

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is amending the animal

drug regulations to reflect approval of a new animal drug application

(NADA) filed by Ciba Animal Health, Ciba-Geigy Corp. The NADA provides

for oral administration of lufenuron tablets to dogs for the prevention

and control of flea populations.

EFFECTIVE DATE: January 4, 1995.

FOR FURTHER INFORMATION CONTACT: Marcia K. Larkins, Center for

Veterinary Medicine (HFV-112), Food and Drug Administration, 7500

Standish Pl., Rockville, MD 20855, 301-594-0614.

SUPPLEMENTARY INFORMATION: Ciba Animal Health, Ciba-Geigy Corp., P.O.

Box 18300, Greensboro, NC 27419-8300, filed NADA 141-035, which

provides for oral administration of Program tablets

containing 45, 90, 204.9, or 409.8 milligrams (mg) of lufenuron per (/)

tablet. Once a month, Program tablets are administered to

dogs, 6 weeks of age and older, at a minimum dosage of 10 mg of

lufenuron/kilogram (4.5 mg/pound) of body weight for the prevention and

control of flea populations. The drug has no deleterious effect on

adult fleas, but it prevents most flea eggs from maturing into adults.

The NADA is approved as of November 23, 1994, and the regulations are

amended in part 520 (21 CFR part 520) by adding new Sec. 520.1288 to

reflect the approval. The basis for approval is discussed in the

freedom of information summary.

In accordance with the freedom of information provisions of part 20

(21 CFR part 20) and Sec. 514.11(e)(2)(ii) (21 CFR 514.11(e)(2)(ii)), a

summary of safety and effectiveness data and information submitted to

support approval of this application may be seen in the Dockets

Management Branch (HFA-305), Food and Drug Administration, rm. 1-23,

12420 Parklawn Dr., Rockville, MD 20857, between 9 a.m. and 4 p.m.,

Monday through Friday.

Section 512(c)(2)(F)(i) of the Federal Food, Drug, and Cosmetic Act

provides a 5-year period of exclusivity to this original NADA beginning

November 23, 1994, because no active ingredient (including any ester or

salt of the active ingredient) has been approved in any other

application under section 512(b)(1) of the act.

The agency has carefully considered the potential environmental

effects of this action. FDA has concluded that the action will not have

a significant impact on the human environment, and that an

environmental impact statement is not required. The agency's finding of

no significant impact and the evidence supporting that finding,

contained in an environmental assessment, may be seen in the Dockets

Management Branch (address above) between 9 a.m. and 4 p.m., Monday

through Friday.

List of Subjects in 21 CFR Part 520

Animal drugs.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under

authority delegated to the Commissioner of Food and Drugs and

redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is

amended as follows:

PART 520-ORAL DOSAGE FORM NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 520 continues to read as

follows:

Authority: Sec. 512 of the Federal Food, Drug, and Cosmetic Act

(21 U.S.C. 360b).

2. New Sec. 520.1288 is added to read as follows:

Sec. 520.1288 Lufenuron tablets.

(a) Specifications. Each tablet contains either 45, 90, 204.9, or

409.8 milligrams of lufenuron.

(b) Sponsor. See No. 058198 in Sec. 510.600(c) of this chapter.

(c) Conditions of use--(1) Amount. 10 milligrams of lufenuron per

kilogram (4.5 milligrams per pound) of body weight.

(2) Indications for use. For use in dogs, 6 weeks of age and older,

for the prevention and control of flea populations.

(3) Limitations. Administer tablet(s) after or in conjunction with

a full meal to ensure adequate absorption. Administer tablet(s) once a

month, preferably on same date each time. All dogs in a household

should be treated to achieve maximum efficacy. Because the drug has no

affect on adult fleas, the concurrent use of insecticides that kill

adults may be required depending on the severity of the infestation.

Federal law restricts this drug to use by or on the order of a licensed

veterinarian.

Dated: December 23, 1994.

Stephen F. Sundlof,

Director, Center for Veterinary Medicine.

[FR Doc. 95-164 Filed 1-3-95; 8:45 am]

BILLING CODE 4160-01-F

This is a copy of a public record, reproduced as it was published. It is not legal advice, and it may not be the version a court would rely on. Check the official source before you cite it.

A word about cookies

We need a few to keep you signed in and the library working. The rest help us see which pages people use and where they get stuck. They stay off unless you say yes.

Oral Dosage Form New Animal Drugs; Lufenuron Tablets · 60 FR 362 | Frix